Autoantibody profile in patients with psoriatic arthritis before and after bdMARD therapy

Authors : Gizem Ayan, Nilüfer Ecem Gezerer, Burçin Şener, Zeynep Sarıbaş, Levent Kılıç, Umut Kalyoncu
Pages : 598-604
Doi:10.18663/tjcl.1819360
View : 34 | Download : 111
Publication Date : 2026-01-01
Article Type : Research Paper
Abstract :Background: This study aimed to evaluate the real-life prevalence of commonly tested autoantibodies among patients with psoriatic arthritis (PsA) treated with biologic agents. Methods Patients with psoriatic arthritis (PsA) from the Hacettepe University Rheumatology Biologic Database (HUR-BIO) were evaluated for antinuclear antibody (ANA), rheumatoid factor (RF), and anti-cyclic citrullinated peptide (anti-CCP) profiles before and after the initiation of biologic therapy. Demographic characteristics, time interval between the laboratory tests and initiation of the biologic agents, seropositivity rates, antibody titers, and ANA pattern subtypes were recorded and analyzed. Results Among 520 patients with psoriatic arthritis (PsA), 69.4% were female, with a mean age of 39.2 ± 5.2 years at diagnosis and a mean disease duration of 3.3 ± 5.2 years. Prior to initiating biologic therapy, 69% of the tested patients demonstrated positivity for at least one autoantibody. ANA exhibited the highest frequency of seropositivity, detected in 40.0% before and 55.3% after biologic treatment. Concurrent RF and anti-CCP positivity were observed in 2.8% and 6.3% of patients before and after treatment, respectively. The most frequent ANA patterns were AC4-5 prior to, and AC1-4-5 following biologic therapy. Among 31 patients with ANA testing available both before and after treatment, 6 (19.4%) converted from negative to positive following biologic treatment. Conclusion: Real-world serological data from patients with PsA in a bDMARD cohort indicated that only 20–30% were seronegative for all three routinely assessed autoantibodies. Consistent with previous reports, ANA positivity rates increased following bDMARD.
Keywords : psoriatik artrit, otoantikorlar, seroloji, biyolojik hastalık modifiye edici ajanlar

ORIGINAL ARTICLE URL